We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

274 hedge funds and large institutions have $3.85B invested in Intra-Cellular Therapies Inc. in 2022 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 103 increasing their positions, 86 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 35

20% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 86

13% more call options, than puts

Call options by funds: $21.3M | Put options by funds: $18.9M

3% more funds holding

Funds holding: 266 → 274 (+8)

16% less capital invested

Capital invested by funds: $4.57B → $3.85B (-$727M)

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
274
Holders Change
+8
Holders Change %
+3.01%
% of All Funds
4.72%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.12%
New
43
Increased
103
Reduced
86
Closed
35
Calls
$21.3M
Puts
$18.9M
Net Calls
+$2.43M
Net Calls Change
-$6.17M

Top Buyers

1
GKIM
GW&K Investment Management
Massachusetts
+$46.1M
2
Invesco
Invesco
Georgia
+$45.3M
3
Millennium Management
Millennium Management
New York
+$42M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$36.3M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$34.3M

Top Sellers

1
Victory Capital Management
Victory Capital Management
Texas
-$43.9M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$36.5M
3
DCM
Driehaus Capital Management
Illinois
-$29.4M
4
SCM
Suvretta Capital Management
New York
-$25.4M
5
CAM
Cormorant Asset Management
Massachusetts
-$15.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
TC
251
Truvestments Capital
Florida
$7K – – –
S
252
SignatureFD
Georgia
$7K +$2.82K +54 +63%
LJHT
253
Laurie J. Hall Trustee
$5K -$2.87K -55 -32%
EW
254
Evoke Wealth
California
$5K – – –
Carson Wealth (CWM LLC)
255
Carson Wealth (CWM LLC)
Nebraska
$5K +$1.2K +23 +28%
DFCM
256
Dark Forest Capital Management
Puerto Rico
$5K +$5.28K +101 +777%
QCG
257
Quadrant Capital Group
Ohio
$4K -$1.57K -30 -27%
WTA
258
Washington Trust Advisors
Massachusetts
$4K – – –
FRA
259
Front Row Advisors
California
$4K +$4.44K +85 New
CA
260
Centerpoint Advisors
Massachusetts
$2K – – –
GRP
261
Global Retirement Partners
California
$2K – – –
MPWT
262
MassMutual Private Wealth & Trust
Connecticut
$2K +$575 +11 +34%
BIA
263
Bell Investment Advisors
California
$1K -$470 -9 -38%
BAM
264
Bellevue Asset Management
Washington
$1K – – –
VCM
265
Versant Capital Management
Arizona
$1K – – –
AAP
266
Arax Advisory Partners
Colorado
$1K +$157 +3 +23%
RCM
267
Raleigh Capital Management
North Carolina
$1K +$836 +16 New
FSWA
268
Financial Synergies Wealth Advisors
Texas
$280 – – –
DCM
269
Driehaus Capital Management
Illinois
– -$29.4M -514,956 Closed
CAM
270
Cormorant Asset Management
Massachusetts
– -$15.7M -275,000 Closed
SPPAM
271
Summit Partners Public Asset Management
Massachusetts
– -$7.9M -138,331 Closed
TLP
272
Tri Locum Partners
New York
– -$6.37M -111,572 Closed
Calamos Advisors
273
Calamos Advisors
Illinois
– -$5.35M -93,772 Closed
Voloridge Investment Management
274
Voloridge Investment Management
Florida
– -$5.28M -92,506 Closed
IHAM
275
Integral Health Asset Management
New York
– -$4.47M -78,277 Closed
9 10
11
12 13

ITCI Hedge Fund Activity: Q3 2022 in Review

274 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2022, worth a combined $3.85B — down 16% from $4.57B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new ITCI positions and 35 closed out — a net gain of 8 holders — while 103 added to existing stakes and 86 trimmed.

The largest buyer was GW&K Investment Management, adding an estimated $46.1M. The largest seller was Victory Capital Management, cutting an estimated $43.9M.

  • 274 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2022, up from 266 in Q2 2022.
  • Funds reported $3.85B of Intra-Cellular Therapies Inc. stock for Q3 2022, down 16% quarter-over-quarter.
  • 43 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2022 and 35 closed out, a net change of +8 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2022 was GW&K Investment Management, an estimated $46.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2022 was Victory Capital Management, an estimated $43.9M sold.

Based on aggregated 13F filings for Q3 2022.